| Ytd | -60.02% | |
| 1y | -76.47% |
| Open | 2.16 | Prev Close | 2.10 | Low | 2.02 | High | 2.29 | Mkt Cap | 35.95M |
| Vol | 138.44K | Avg Vol | 44.69K | EPS | -0.50 | P/E | -4.15 | Forward P/E | N/A |
| Beta | 1.49 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 2.79 | 200-d Avg | 4.69 | 1yr Est | 14.67 |
BHST News
BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript
BioHarvest Sciences NASDAQ: BHST reported second-quarter 2026 revenue of $8.8 million, up 3.8% from
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported higher second-quarter revenue as the plant-
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks C
Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production prog
Exclusive agreement through 2027 and 2028 is estimated to generate $20-$30 million in revenue Positi
Nu Skin Enterprises (NYSE: NUS - Get Free Report) and BioHarvest Sciences (NASDAQ: BHST - Get Free R
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Scien
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Scien
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has received a 4.33 million NIS
BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and su
Grant will partially fund research to enable faster development, with a higher probability of succes
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Scien
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Scien
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration wit
Expanded sweetener molecule development program aims to broaden access to plant-based sweetening sol
BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript
BioHarvest Sciences NASDAQ: BHST reported higher first-quarter revenue and reiterated its 2026 outlo
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.11 per share versus the Zacks C
Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDM
Business development appointment is aligned with securing long-term customers for development and ma
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said that it has completed the first stage of a mult
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of
